首页 | 本学科首页   官方微博 | 高级检索  
     

硼替佐米对多发性骨髓瘤患者止凝血功能的影响
引用本文:朱琦,唐勇,姚一芸,邹丽芳,窦红菊,汪雷,胡钧培. 硼替佐米对多发性骨髓瘤患者止凝血功能的影响[J]. 血栓与止血学, 2011, 17(2): 73-75
作者姓名:朱琦  唐勇  姚一芸  邹丽芳  窦红菊  汪雷  胡钧培
作者单位:上海交通大学医学院附属第九人民医院血液科,上海,200011
摘    要:目的探究硼替佐米对多发性骨髓瘤患者止凝血功能的影响。方法动态检测和比较22例多发性骨髓瘤患者静脉输注硼替佐米前后血浆内皮素-1和凝血酶调节蛋白水平以及血小板最大聚集率和凝血因子Ⅱ、Ⅴ、Ⅶ、Ⅷ、Ⅸ、Ⅹ、Ⅺ活性、蛋白C、蛋白S和抗凝血酶活性、纤维蛋白原和血浆D二聚体含量,组织型纤溶酶原激活物、纤溶酶原激活抑制物、α2抗纤溶酶抑制物的活性。结果静脉输注硼替佐米1 h后,多发性骨髓瘤患者体内凝血酶调节蛋白水平比输注前显著升高(P〈0.05),而血小板最大聚集率比输注前明显降低(P〈0.01),其余指标无明显改变。结论硼替佐米可能通过抑制血小板聚集和调变血管内皮细胞抗凝活性而降低多发性骨髓瘤患者并发动静脉血栓的风险。

关 键 词:硼替佐米  多发性骨髓瘤  止凝血功能

Influences of Bortezomib on Haemostatic Function in Patients with Multiple Myeloma
ZHU Qi,TANG Yong,YAO Yi-yun,ZOU Li-fang,DOU Hong-ju,WANG Lei,HU Jun-pei. Influences of Bortezomib on Haemostatic Function in Patients with Multiple Myeloma[J]. Chinese Journal of Thrombosis and Hemostasis, 2011, 17(2): 73-75
Authors:ZHU Qi  TANG Yong  YAO Yi-yun  ZOU Li-fang  DOU Hong-ju  WANG Lei  HU Jun-pei
Affiliation:ZHU Qi,TANG Yong,YAO Yi-yun,ZOU Li-fang,DOU Hong-ju,WANG Lei,HU Jun-pei (Department of Hematology,Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao tong University School of Medicine,Shanghai,200011,China)
Abstract:Objective To investigate the influences of bortezomib on haemostatic function in patients with multiple myeloma.Methods The markers of haemostatic function were evaluated,which included serum levels of endothelin-1 and thrombomodulin,platelet maximal aggregation rate,fibrinogen and its degradation products D-dimer as well as activities of coagulation factors Ⅱ,Ⅴ,Ⅶ,Ⅷ,Ⅸ,Ⅹ,Ⅺ,proteins C,S and antithrombin,tissue plasminogen activator,plasminogen activator inhibitor and α2-plasmin inhibitor,during treatment with bortezomib in 22 patients with multiple myeloma.Results One hour after bortezomib infusion,it was found that the serum levels of thrombomodulin significantly increased(P0.05),while platelet maximal aggregation rate dramatically decreased(P0.01) in patients with multiple myeloma.Other parameters were not statistically changed by bortezomib.Conclusion Bortezomib might decrease risks of arterial or venous thrombosis in patients with multiple myeloma through its inhibitory effect on platelet aggregation as well as modulation of endothelium anticoagulation function.
Keywords:Bortezomib  Multiple myeloma  Haemostatic function  
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号